Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-301
- Development stage
- Unknown
- Lead developer
- Proterris
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
PRO-301 is an inhaled formulation of carbon monoxide (iCO) being developed by Proterris for the prevention of Delayed Graft Function (DGF) in kidney transplant recipients. The therapeutic approach leverages the cytoprotective, anti-inflammatory, and anti-apoptotic properties of carbon monoxide to mitigate ischemia-reperfusion injury (IRI), which is a primary cause of DGF. By delivering low doses of carbon monoxide via inhalation, the drug aims to activate protective cellular pathways, such as the induction of heme oxygenase-1 (HO-1) and the modulation of mitochondrial function, thereby improving graft survival and function post-transplantation. PRO-301 is currently in Phase 2 development.
- Other names
- inhaled carbon monoxideiCO
Beyond the preview
Go deeper on PRO-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-301.